About Viyash
Viyash is a Healthcare company based in Hyderabad (India) founded in 2019 by Srihari Raju Kalidindi and Haribabu Bodepudi. APIs and intermediates are manufactured by Viyash as a CDMO. Viyash has raised $120.02 million across 2 funding rounds from investors including The Carlyle Group, Veeramachaneni Sirisha and Bodepudi Vls Kumari. Viyash has completed 1 acquisition, including Symed. Viyash was last valued at $249.09 million in July 2021. Its chief executive, as recorded, is Haribabu Bodepudi. Its Indian entity Viyash Life Sciences Private Limited reported revenue of ₹228 Cr. Viyash offers products and services including Finished Dosages, APIs, and Intermediates. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Inventys, Blue Jet Healthcare and Ami organics; 1 of its 3 listed competitors has raised funding.
Company details
Viyash was established in 2019 in Hyderabad, India, as a contract development and manufacturing organization. Focus is placed on the production of active pharmaceutical ingredients and intermediates within the pharmaceutical sector. Operations are managed from the companys base in India, with leadership provided by co-founders Haribabu Bodepudi as CEO and Srihari Raju Kalidindi as COO. Services encompass development and manufacturing for pharmaceutical needs.
- Headquarters Hyderabad, India
- Founders Srihari Raju Kalidindi, Haribabu Bodepudi
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Website viyash.com
- Social LinkedIn
- Legal Name Viyash Life Sciences Private Limited
- Date of Incorporation 21 Feb, 2019
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹228 Cr
FY 2025 · +9% YoY
- Net Loss-₹16.46 Cr
FY 2025 · -1% margin
- EBITDA₹167 Cr
FY 2025 · 11% margin
- Total Equity Funding$120.02M (USD)
in 2 rounds
- Latest Funding Round$111.96M (USD), Angel Round
Jul 2021
- InvestorsThe Carlyle Group
& 38 more
- Investments & Acquisitions
Associated legal entities of Viyash
Viyash operates through Viyash Life Sciences Private Limited (amalgamated). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Viyash Life Sciences Private Limited CIN U24239TG2019PTC130774 | Amalgamated | 21 Feb 2019 | Hyderabad, Telangana | ₹228 Cr | 278 | 10 | View details |
Products & Services of Viyash
Viyash offers a comprehensive portfolio of products and services, including Finished Dosages, APIs, and Intermediates.
Manufactured formulations for animal health and treatment applications
Essential components for pharmaceutical drug production processes
Precursors used in synthesizing active pharmaceutical ingredients
Funding Insights of Viyash
Viyash has successfully raised a total of $120.02M across 2 strategic funding rounds. The most recent funding activity was a Angel Round of $111.96 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120.02M
- Total Rounds 2
- Last Round Angel Round — $111.96M
- First Round $8.07M
(Mar 2020)
- Investors Count 39
All 2 funding rounds of Viyash with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $111.96M | Angel Round | $249.09M | Veeramachaneni Sirisha, Bodepudi Vls Kumari | |
| Mar 2020 | $8.07M | Angel Round | $66.09M | Dayakar Reddy Mallu, Gsr Anjaneyulu |
| Date | Valuation | Stage |
|---|---|---|
| Jul 2021 | $249.09M | •••••••• |
| Mar 2020 | $66.09M | •••••••• |
Last known valuation $249.09M (Jul 2021). 39 investors in total: 1 institutional and 38 angel.
Investors in Viyash
Viyash has secured backing from 39 investors, including angel and venture fund investors. Prominent investors backing the company include The Carlyle Group, Veeramachaneni Sirisha and Bodepudi Vls Kumari.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward multiple sectors. | 1986 | carlyle.com | ||
VS Veeramachaneni Sirisha | unknown_b5b5b10b29a941628 | |||
BV Bodepudi Vls Kumari | unknown_2fc0a257c1c346f49 | |||
KK Kota Krishna Rao | unknown_ef570de9a225495db | |||
HB Haribabu Bodepudi | unknown_94d06cb34081495f9 | |||
SR Srihari Raju Kalidindi | unknown_aa36c50eff9149898 | |||
DR Dayakar Reddy Mallu | unknown_6f03b5f6cd884002a | |||
GA Gsr Anjaneyulu | unknown_2fe8522d15de4f71b | |||
SR Suryanarayana Raju Vegesna | unknown_ba015b670e714dfb8 | |||
SP Satya Preethi Gadde | unknown_055c13060871443ba |
Investor details for Viyash
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Viyash Life Sciences Private Limited (Viyash)
Viyash Life Sciences Private Limited is the primary company behind Viyash. The board of Viyash Life Sciences Private Limited currently have 8 directors; the longest-serving is Hari Babu Bodepudi, appointed in 2019. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Hari Babu Bodepudi DIN 01119687 | Whole-time director | 21 Feb 2019 | 7 yrs 8 mo | Viyash Life Sciences Private Limited |
| Kalidindi Srihari Raju DIN 00982034 | Whole-time director | 07 Aug 2019 | 7 yrs 3 mo | Viyash Life Sciences Private Limited |
| Pradip Manilal Kanakia DIN 00770347 | Director | 20 Dec 2021 | 4 yrs 10 mo | Viyash Life Sciences Private Limited |
| Gurveen Singh DIN 09507365 | Director | 24 Mar 2022 | 4 yrs 7 mo | Viyash Life Sciences Private Limited |
| Kamal Kishore Sharma DIN 00209430 | Director | 01 Dec 2022 | 3 yrs 11 mo | Viyash Life Sciences Private Limited |
| Sunil Kaul DIN 05102910 | Nominee Director | 04 Jan 2023 | 3 yrs 10 mo | Viyash Life Sciences Private Limited |
| Amit Jain DIN 06917608 | Nominee Director | 04 Jan 2023 | 3 yrs 10 mo | Viyash Life Sciences Private Limited |
| Anuj Vishnukumar Poddar DIN 01908009 | Director | 13 Nov 2024 | 1 yr 11 mo | Viyash Life Sciences Private Limited |
People of Viyash
10 people are tracked at Viyash (7 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
| Co-Founder & COO | Leadership | |
| Co-Founder & CEO | Leadership | |
Rajkamal Varshney | Senior Vice President - Marketing & Business Development | Leadership |
Madhuveer Yadavalli | Senior General Manager | Leadership |
Sivakumar Battina | Vice President | Leadership |
Gowtham Reddy .regalla | Assistant General Manager | Leadership |
Ramakant Singani | Chief Financial Officer | Leadership |
Srikanth Saripalli | Engineer | Team |
Rajesh Siripurapu | Senior Executive HR (corporate Office) | Team |
Pocha Venkateswara Reddy | Assistant Manager | Team |
Complete people profiles for Viyash
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Viyash
Figures of Viyash Life Sciences Private Limited, the primary company behind Viyash, for FY 2025. Revenue was ₹228 Cr (+9% year on year). Net loss was -₹16.46 Cr (-1% margin). EBITDA was ₹167 Cr (11% margin). Revenue has grown at a compounded annual rate of +17% over three years.
- ₹228 CrRevenue · FY 2025 · +9% YoY
- -₹16.46 CrNet loss · -1% margin
- ₹167 CrEBITDA · 11% margin
- ₹343 CrPaid-up capital
- 278Employees (provident fund records)
- +17%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Viyash Life Sciences Private Limited are on its company page.
Detailed financial statements for Viyash
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Viyash
Viyash has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Symed.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
APIs are manufactured and drug development services are provided. | symedlabs.com | Hyderabad, India | 1997 | Nov 2021 | •••• |
Complete acquisition details for Viyash
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Viyash
5 dated milestones of Viyash across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Viyash is founded.
- Funding First funding round of $8.1M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Angel Round, of $112.0M.
- Acquisition Acquires Symed.
Competitors of Viyash
Viyash has 3 listed competitors in our database, 1 of them funded. They include Inventys, Blue Jet Healthcare and Ami organics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inventys.in | 2005 | Mumbai, India | $64.34M | 219 | Actives, advanced intermediates, and specialty chemicals are custom manufactured. | |
| bluejethealthcare.com | 1969 | Mumbai, India | 476 | CDMO focused on manufacturing, supplier, and development of intermediates & APIs | ||
| amiorganics.com | 2007 | Surat, India | 4 | Advanced API intermediates are manufactured for pharmaceutical use. |
Detailed competitors of Viyash
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Viyash
The website of Viyash (viyash.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 3.4% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Viyash (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Viyash
Complete news archive for Viyash
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viyash
Viyash was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Viyash is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Haribabu Bodepudi is the CEO of Viyash, as recorded in our data. They have also founded this company.
Viyash is a funded company, having raised a total of $120.02M across 2 funding rounds to date. The company's 1st funding round was a Angel Round of $8.07M, raised on Mar 2020.
The primary company behind Viyash, Viyash Life Sciences Private Limited, reported revenue of ₹228 Cr for FY 2025, up 9% year on year.
Viyash was established in 2019 in Hyderabad, India, as a contract development and manufacturing organization. Focus is placed on the production of active pharmaceutical ingredients and intermediates within the pharmaceutical sector. Operations are managed from the companys base in India, with leadership provided by co-founders Haribabu Bodepudi as CEO and Srihari Raju Kalidindi as COO. Services encompass development and manufacturing for pharmaceutical needs.
Viyash's top competitors include Inventys, Blue Jet Healthcare and Ami organics.
Viyash offers Finished Dosages, APIs, and Intermediates.
Viyash has made 1 acquisition, including Symed.
Viyash has 39 investors. Key investors include The Carlyle Group, Veeramachaneni Sirisha, Bodepudi Vls Kumari, Kota Krishna Rao, and Haribabu Bodepudi.
The valuation of Viyash is $249.09M as of Jul 2021.
Viyash operates through Viyash Life Sciences Private Limited.